Genasense Melanoma Progression-Free Survival Data Do Not Show "Real Effect," Cmte. Says

Committee votes 13 to 3 that substantial evidence of effectiveness has not been demonstrated for Aventis/Genta's Genasense in metastatic melanoma. FDA and committee cite concerns about the way progression-free survival and response data were collected.